Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line Cryoablation vs AAD for Persistent AF
NCT05939076Phase 3Not yet recruiting
- Sponsor
- Region Örebro län
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Countries
- 4
01
Overview
Phase 3, randomised, single-blind trial in Atrial fibrillation (AFib) (2 arms), sponsored by Region Örebro län. Primary endpoint: Proportion of patients free from first atrial tachyarrhythmia recurrence lasting 6 minutes or longer at 12 months. Planned start Aug 2023; status: not yet recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05939076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939076.